Same Name, Different Game: EGFR Drives Intrinsic KRAS^G12C Inhibitor Resistance in Colorectal Cancer Available to Purchase

The discovery of covalent inhibitors of KRAS^G12C has led to promising clinical results in lung cancer, but disappointing response rates in colon cancer. In this issue of Cancer Discovery, Misale and colleagues identify high endogenous EGFR activity as the underlying mechanism of intrinsic resistance, which can be overcome by anti-EGFR antibody coadministration.

See related article by Amodio et al., p. 1129.